James Trevor Pringle

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Botry-Zen Ltd. operates as a bio tech company, which manufactures and sells biological, organic and natural fungicides for the New Zealand, United States and European horticultural markets. Its products include BOTRY-Zen, MIDI-Zen and ARMOUR-Zen. The company was founded in April 2001 and is headquartered in Dunedin, New Zealand.

Christchurch City Holdings Ltd. operates as an investment arm of Christchurch City Council. It engages in non-political buffer between the Council and the companies it owned. The company was founded in 1993 and is headquartered in Christchurch, New Zealand.

Ngai Tahu Holdings Corp. Ltd. operates as an investment firm. It is a long-term intergenerational New Zealand focused investor with an active approach to investment, managing assets and governance. The company is headquartered in Christchurch, New Zealand.

Part of Genesis Research & Development Corp. Ltd., BioStore NZ Ltd. operates a pharmaceutical company. The company is based in Auckland, New Zealand.

Gould Holdings Ltd. provides financial investment services. It offers its services to facilitate the flow of money, investment-related services, stock exchange, and associated marketing services as well as oversight services, which include accounting, regulatory agencies, and data oversight. The company was founded on August 26, 1999 and is headquartered in Amberley, New Zealand.

Wool Research Organisation of New Zealand, Inc. provides research and development services for the wool industry. It specializes in investing in commodity contracts, tax liens, venture capital companies, and other miscellaneous investing. The company is headquartered in Christchurch, New Zealand.

Bank of New Zealand Ltd. engages in the provision of banking and financial products and services. It operates through the following segments: Partnership Banking; and Corporate and Institutional Banking. The company was founded on July 29, 1861 and is headquartered in Auckland, New Zealand.

Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London.

CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.

Part of AgResearch Ltd., Orico Ltd. engages in the research and development of biotechnology and muscle growth therapeutics in livestock. The company is based in Dunedin, New Zealand.

Part of AgResearch Ltd., Paraco Ltd. engages in the research and development of parasite technology for sheep. The company is based in Hamilton, New Zealand. Paraco was acquired by AgResearch Ltd. on August 05, 2008.

EnCoate Holdings Ltd. develops food-grade biopolymer technologies. The company was founded in 2003 and is headquartered in Lincoln, New Zealand.

Biomatters Ltd. engages in the design of bioinformatics software for molecular biologists and biochemists. It specializes in software development, biotechnology, bioinformatics, sequence analysis, next-generation sequencing, genomics, DNA sequence alignment, assembly and analysis. The firm's products include Geneious, Genome and Melanoma. The company was founded by Daniel Batten, Alexei J. Drummond, Athena Ferreira and Julio Ferreira in 2003 and is headquartered in Auckland, New Zealand.

Keraplast Manufacturing provides personal care products in nutritional and medical areas. It builds blocks at a cellular level, giving the human body structure and order and also develops healthy tissues, including skin, hair and nails. The company is headquartered in Lincoln, New Zealand.

Migco Pharmaceuticals Ltd. develops new drug therapeutic products. The firm is focused on developing new drug therapies for the prevention and treatment of migraine headaches. It has clinical safety data for its lead compound MGX-008. The company was founded by Larry Ellsworth Stenswick in 2004 and is headquartered in Rangiora, New Zealand.

Landcare Research New Zealand Ltd. manages terrestrial biodiversity and land resources. It provides science solutions for the wise use and care of land environments. The firm works across sectors, scales, time frames and cultures to address the national issues confronting New Zealand’s terrestrial ecosystems. The company was founded in 1992 and is headquartered in Lincoln, New Zealand.

Focus Genetics SA Ltd. engages in livestock genetics research and development. It enhances genetics in sheep, cattle and deer and markets these genetics to farmers throughout New Zealand. The company was founded on June 29, 2007 and is headquartered in Napier, New Zealand.

Iconic Investments Ltd. provides investment advice. The private company is based in Christchurch, New Zealand.

Prime Management Ltd. provides independent fund administration services. The private company is based in Christchurch, New Zealand.

Part of Wool Equities Ltd., Bruce Woollen Mill Ltd. is a New Zealander company that manufactures yarn and wool based textile products. The company is based in Christchurch, New Zealand.

CuroNZ Ltd. is a clinical stage neurotherapeutics company based in Wellsford, New Zealand. The New Zealander company's vision is to transform the quality of life for severely neurologically affected children and adult patients. CuroNZ Ltd. focuses on developing a body and mind boosting drug therapy using a modified naturally occurring molecule called nrp2945. This molecule controls seizure activity and improves comorbidities in patients diagnosed with epileptic encephalopathy syndromes like Lennox-Gastaut syndrome and drug-resistant temporal lobe epilepsy. CuroNZ's peptide drug, nrp2945, has a minimal adverse event profile and is administered through subcutaneous injections every other day. The company has conducted successful phase I safety trials in healthy volunteers and a small phase II trial in patients with absence epilepsy.